BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019;30:1856-83. [PMID: 31549998 DOI: 10.1093/annonc/mdz400] [Cited by in Crossref: 115] [Cited by in F6Publishing: 207] [Article Influence: 57.5] [Reference Citation Analysis]
Number Citing Articles
1 Zbitou A, Desandes E, Guissou S, Mallebranche C, Lacour B. Thyroid cancers in children and adolescents in France: Incidence, survival and clinical management over the 2000–2018 period. International Journal of Pediatric Otorhinolaryngology 2022;162:111325. [DOI: 10.1016/j.ijporl.2022.111325] [Reference Citation Analysis]
2 Zhang Z, Mo Y, Wu L, Wang X, Liao G, Tan W, Li D. Circ_0002111 modulates the growth process of papillary thyroid carcinoma cells by targeting the miR-363-3p/HMGB1 axis. Anticancer Drugs 2022;33:923-34. [PMID: 36136992 DOI: 10.1097/CAD.0000000000001382] [Reference Citation Analysis]
3 Koutras A, Ntounis T, Fasoulakis Z, Papalios T, Pittokopitou S, Prokopakis I, Syllaios A, Valsamaki A, Chionis A, Symeonidis P, Samara AA, Pagkalos A, Pergialiotis V, Theodora M, Antsaklis P, Daskalakis G, Kontomanolis EN. Cancer Treatment and Immunotherapy during Pregnancy. Pharmaceutics 2022;14:2080. [DOI: 10.3390/pharmaceutics14102080] [Reference Citation Analysis]
4 Zhu J, Sun K, Wang J, He Y, Li D, Liu S, Huang Y, Zhang M, Song B, Liao X, Liang H, Zhang Q, Shi M, Guo L, Zhou Y, Lin Y, Lu Y, Tuo J, Xia Y, Sun H, Xiao H, Ji Y, Yan C, Qiao J, Zeng H, Zheng R, Zhang S, Liu S, Chang S, Wei W. Clinicopathological and surgical comparisons of differentiated thyroid cancer between China and the USA: A multicentered hospital-based study. Front Public Health 2022;10:974359. [DOI: 10.3389/fpubh.2022.974359] [Reference Citation Analysis]
5 Wang B, Zhu C, Liu H, Yao X, Wu J. Relationship between pretracheal and/or prelaryngeal lymph node metastasis and paratracheal and lateral lymph node metastasis of papillary thyroid carcinoma: A meta-analysis. Front Oncol 2022;12:950047. [DOI: 10.3389/fonc.2022.950047] [Reference Citation Analysis]
6 Almeida SD, Oliveira FPM, Oliveira MJ, Oliveira JM, Afonso R, Faria DB, Costa DC. Brain [18F]Fluorodeoxyglucose Metabolism Assessment under Hypothyroidism and Recombinant Human Thyroid-Stimulating Hormone in Comparison with Thyroid Hormone Replacement in Patients Submitted to Total Thyroidectomy. Applied Sciences 2022;12:9437. [DOI: 10.3390/app12199437] [Reference Citation Analysis]
7 Su Y, Li C, Fang Y, Gu X, Zheng Q, Lu J, Li L. The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility. Clin Transl Oncol 2022. [PMID: 36131071 DOI: 10.1007/s12094-022-02944-2] [Reference Citation Analysis]
8 Perivoliotis K, Samara AA, Koutoukoglou P, Ntellas P, Dadouli K, Sotiriou S, Ioannou M, Tepetes K. Microvessel density in differentiated thyroid carcinoma: A systematic review and meta-analysis. World J Methodol 2022; 12(5): 448-458 [DOI: 10.5662/wjm.v12.i5.448] [Reference Citation Analysis]
9 Gong L, Liu Y, Guo X, Wang C, Yan F, Liu J, Hou X, Chen L, Liang K. BRAF p.V600E genetic testing based on ultrasound-guided fine-needle biopsy improves the malignancy rate in thyroid surgery: our single-center experience in the past 10 years. J Cancer Res Clin Oncol 2022. [PMID: 36070149 DOI: 10.1007/s00432-022-04235-3] [Reference Citation Analysis]
10 Qi Y, Liu J, Liu Y, Shen Z, Hu N. Ectopic papillary thyroid carcinoma mimicking distant metastatic tissue. J Int Med Res 2022;50:3000605221121968. [PMID: 36129883 DOI: 10.1177/03000605221121968] [Reference Citation Analysis]
11 Kong M, Guo Q, Zhou S, Li M, Kuang K, Huang Z, Wu F, Chen X, Zhu Q. Attribute-aware interpretation learning for thyroid ultrasound diagnosis. Artificial Intelligence in Medicine 2022;131:102344. [DOI: 10.1016/j.artmed.2022.102344] [Reference Citation Analysis]
12 Shao C, Li Z, Zhang C, Zhang W, He R, Cai Y, Xu J. Optical diagnostic imaging and therapy for thyroid cancer. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100441] [Reference Citation Analysis]
13 Shi Z, Zhang S, Li C, Fan D, Xue Y, Cheng Z, Wu L, Lu K, Wu Z, Li X, Liu H, Li S. Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. Front Immunol 2022;13:966550. [DOI: 10.3389/fimmu.2022.966550] [Reference Citation Analysis]
14 Kwon H, Lim W, Moon B. Number of Tumor Foci as a Risk Factor for Recurrence in Papillary Thyroid Carcinoma: Does It Improve Predictability? Cancers 2022;14:4141. [DOI: 10.3390/cancers14174141] [Reference Citation Analysis]
15 Koimtzis G, Stefanopoulos L, Alexandrou V, Tteralli N, Brooker V, Alawad AA, Carrington-Windo E, Karakasis N, Geropoulos G, Papavramidis T. The Role of Carbon Nanoparticles in Lymph Node Dissection and Parathyroid Gland Preservation during Surgery for Thyroid Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:4016. [PMID: 36011009 DOI: 10.3390/cancers14164016] [Reference Citation Analysis]
16 Fan X, Xie F, Zhang L, Tong C, Zhang Z. Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer. Front Mol Biosci 2022;9:961450. [DOI: 10.3389/fmolb.2022.961450] [Reference Citation Analysis]
17 Oliinyk D, Augustin T, Rauch J, Koehler VF, Belka C, Spitzweg C, Käsmann L. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study. J Cancer Res Clin Oncol 2022. [PMID: 35960373 DOI: 10.1007/s00432-022-04223-7] [Reference Citation Analysis]
18 Houten PV, Netea-Maier RT, Smit JW. Differentiated thyroid carcinoma: An update. Best Pract Res Clin Endocrinol Metab 2022;:101687. [PMID: 36002346 DOI: 10.1016/j.beem.2022.101687] [Reference Citation Analysis]
19 Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med 2022. [PMID: 35962206 DOI: 10.1038/s41591-022-01931-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Leuștean L, Ungureanu MC, Preda C, Bilha SC, Obrocea F, Dănilă R, Stătescu L, Apostol Ciobanu DG. Management of malignant struma ovarii: is aggressive therapy justified? Case report and literature review. Thyroid Res 2022;15:14. [PMID: 35948940 DOI: 10.1186/s13044-022-00132-6] [Reference Citation Analysis]
21 Garcia-alvarez A, Hernando J, Carmona-alonso A, Capdevila J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol 2022;13:929091. [DOI: 10.3389/fendo.2022.929091] [Reference Citation Analysis]
22 Zhang Q, Qu K, Wang Z, Gao J, Zhang Y, Cao W. Clinical application of parathyroid autotransplantation in endoscopic radical resection of thyroid carcinoma. Front Oncol 2022;12:942488. [DOI: 10.3389/fonc.2022.942488] [Reference Citation Analysis]
23 Sparano C, Moog S, Hadoux J, Dupuy C, Al Ghuzlan A, Breuskin I, Guerlain J, Hartl D, Baudin E, Lamartina L. Strategies for Radioiodine Treatment: What’s New. Cancers 2022;14:3800. [DOI: 10.3390/cancers14153800] [Reference Citation Analysis]
24 Kaliszewski K, Ludwig M, Ludwig B, Mikuła A, Greniuk M, Rudnicki J. Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years? Cancers (Basel) 2022;14:3643. [PMID: 35892901 DOI: 10.3390/cancers14153643] [Reference Citation Analysis]
25 Zhu X, Chen C, Guo Q, Ma J, Sun F, Lu H. Deep Learning-Based Recognition of Different Thyroid Cancer Categories Using Whole Frozen-Slide Images. Front Bioeng Biotechnol 2022;10:857377. [PMID: 35875502 DOI: 10.3389/fbioe.2022.857377] [Reference Citation Analysis]
26 Anwar SL, Cahyono R, Suwardjo S, Hardiyanto H. Extrathyroidal extension and cervical node infiltration are associated with recurrences and shorter recurrence-free survival in differentiated thyroid cancer: a cohort study. Thyroid Res 2022;15:13. [PMID: 35883150 DOI: 10.1186/s13044-022-00131-7] [Reference Citation Analysis]
27 Peng W, Li W, Zhang X, Cen W, Liu Y. The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication. J Clin Lab Anal 2022;:e24609. [PMID: 35838025 DOI: 10.1002/jcla.24609] [Reference Citation Analysis]
28 Evans C, Lotz J, Bhandari M, Hellier RT, Wang XY, Lott R, Lackner KJ, Müller R, Kulasingam V. Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay. J Clin Lab Anal 2022;:e24595. [PMID: 35837992 DOI: 10.1002/jcla.24595] [Reference Citation Analysis]
29 Lin J, Qiu Y, Zheng X, Dai Y, Xu T. The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma. BMC Cancer 2022;22:756. [PMID: 35818041 DOI: 10.1186/s12885-022-09838-0] [Reference Citation Analysis]
30 Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Lucia P, Verrienti A, Filetti S, Durante C. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment. Endocrine 2022. [PMID: 35802229 DOI: 10.1007/s12020-022-03131-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Puliafito I, Esposito F, Prestifilippo A, Marchisotta S, Sciacca D, Vitale MP, Giuffrida D. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects. Front Endocrinol 2022;13:860671. [DOI: 10.3389/fendo.2022.860671] [Reference Citation Analysis]
32 Czajkowski M, Kaemmerer D, Sänger J, Sauter G, Wirtz RM, Schulz S, Lupp A. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies. BMC Cancer 2022;22:740. [PMID: 35799158 DOI: 10.1186/s12885-022-09839-z] [Reference Citation Analysis]
33 Chen B, Lei S, Yin X, Fei M, Hu Y, Shi Y, Xu Y, Fu L. Mitochondrial Respiration Inhibition Suppresses Papillary Thyroid Carcinoma Via PI3K/Akt/FoxO1/Cyclin D1 Pathway. Front Oncol 2022;12:900444. [DOI: 10.3389/fonc.2022.900444] [Reference Citation Analysis]
34 Ou D, Chen C, Jiang T, Xu D. Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma. Front Oncol 2022;12:859396. [DOI: 10.3389/fonc.2022.859396] [Reference Citation Analysis]
35 Liu W, Yan X, Dong Z, Su Y, Ma Y, Zhang J, Diao C, Qian J, Ran T, Cheng R. A Mathematical Model to Assess the Effect of Residual Positive Lymph Nodes on the Survival of Patients With Papillary Thyroid Microcarcinoma. Front Oncol 2022;12:855830. [DOI: 10.3389/fonc.2022.855830] [Reference Citation Analysis]
36 Liu F, Zhou Y, Song W, Wang H, Zakaly H. Cold Atmospheric Plasma Inhibits the Proliferation of CAL-62 Cells through the ROS-Mediated PI3K/Akt/mTOR Signaling Pathway. Science and Technology of Nuclear Installations 2022;2022:1-12. [DOI: 10.1155/2022/3884695] [Reference Citation Analysis]
37 Taelman V, Boer M, Taelman P. Metastatic malignant struma ovarii: a case report and review of the literature on the management of malignant struma ovarii. Acta Clin Belg 2022;77:721-5. [PMID: 34191687 DOI: 10.1080/17843286.2021.1944583] [Reference Citation Analysis]
38 Ma LX, Espin-Garcia O, Bedard PL, Stockley T, Prince R, Mete O, Krzyzanowska MK. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. Thyroid 2022;32:657-66. [PMID: 35262412 DOI: 10.1089/thy.2021.0542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Donckier JE, Fervaille C, Bertrand C. Occurrence of sporadic medullary thyroid carcinoma in Graves' disease in association with a RET proto-oncogene mutation. Acta Clin Belg 2022;77:596-9. [PMID: 33913798 DOI: 10.1080/17843286.2021.1920124] [Reference Citation Analysis]
40 Yang K, Chen J, Wu H, Tian H, Ye X, Xu J, Luo X, Dong F. S-Thyroid Computer-Aided Diagnosis Ultrasound System of Thyroid Nodules: Correlation Between Transverse and Longitudinal Planes. Front Physiol 2022;13:909277. [DOI: 10.3389/fphys.2022.909277] [Reference Citation Analysis]
41 Tuncel M, Vrachimis A, Campenni A, de Keizer B, Verburg FA, Kreissl MC, Ovcaricek PP, Geliashvili T, Giovanella L. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. Eur J Nucl Med Mol Imaging 2022. [PMID: 35581502 DOI: 10.1007/s00259-022-05841-6] [Reference Citation Analysis]
42 Innaro N, Gervasi R, Ferrazzo T, Garo NC, Curto LS, Lavecchia A, Aquila I, Donato G, Malara N. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell-based cytology. Cancer Med 2022. [PMID: 35586892 DOI: 10.1002/cam4.4813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Turla A, Zamparini M, Milione M, Grisanti S, Amoroso V, Pedersini R, Cosentini D, Berruti A. Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis. Front Endocrinol (Lausanne) 2022;13:871210. [PMID: 35528006 DOI: 10.3389/fendo.2022.871210] [Reference Citation Analysis]
44 Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaïd I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35546184 DOI: 10.1038/s41585-022-00592-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Leboulleux S, Lamartina L, Hadoux J, Baudin E, Schlumberger M. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. Expert Opin Investig Drugs 2022. [PMID: 35522027 DOI: 10.1080/13543784.2022.2071696] [Reference Citation Analysis]
46 Qu N, Hui Z, Shen Z, Kan C, Hou N, Sun X, Han F. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development. Front Endocrinol 2022;13:873027. [DOI: 10.3389/fendo.2022.873027] [Reference Citation Analysis]
47 Inés C, Fabián P, Roxana C, Alejandra S, José BM. Prospective study on the clinical relevance of 18F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma. Endocrine 2022. [PMID: 35489000 DOI: 10.1007/s12020-022-03062-3] [Reference Citation Analysis]
48 Kanokwongnuwat W, Larbcharoensub N, Sriphrapradang C, Suppasilp C, Thamnirat K, Sakulpisuti C, Kositwattanarerk A, Utamakul C, Sritara C, Chamroonrat W. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center. Endocrine 2022. [PMID: 35476179 DOI: 10.1007/s12020-022-03060-5] [Reference Citation Analysis]
49 Wu M, Ou-yang D, Wei B, Chen P, Shi Q, Tan H, Huang B, Liu M, Qin Z, Li N, Hu H, Huang P, Chang S. A Prognostic Model of Differentiated Thyroid Cancer Based on Up-Regulated Glycolysis-Related Genes. Front Endocrinol 2022;13:775278. [DOI: 10.3389/fendo.2022.775278] [Reference Citation Analysis]
50 Zhu Y, Peng X, Zhou Q, Tan L, Zhang C, Lin S, Long M. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis 2022;13:358. [PMID: 35436987 DOI: 10.1038/s41419-022-04817-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Dai J, Zhang Y, Yin Z, Lv Z. A combined nano-carbon tracer and nano-fluorescence assay for parathyroid misresection reduction in thyroid surgery. Arabian Journal of Chemistry 2022;15:103709. [DOI: 10.1016/j.arabjc.2022.103709] [Reference Citation Analysis]
52 Kim S, Bang JI, Boo D, Kim B, Choi IY, Ko S, Yoo IR, Kim K, Kim J, Joo Y, Ryoo HG, Paeng JC, Park JM, Jang W, Kim B, Chung Y, Yang D, Yoo S, Lee HY. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging 2022. [PMID: 35362796 DOI: 10.1007/s00259-022-05779-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K, Papotti M, Berruti A. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
54 Román-gil MS, Pozas J, Rosero-rodríguez D, Chamorro-pérez J, Ruiz-granados Á, Caracuel IR, Grande E, Molina-cerrillo J, Alonso-gordoa T. Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies. Cancer Treatment Reviews 2022;105:102372. [DOI: 10.1016/j.ctrv.2022.102372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Guo F, Xu L, Zhang J. Use of Near-Infrared Autofluorescence Imaging During Thyroidectomy Associated with Improved Clinical Outcomes. Indian J Surg. [DOI: 10.1007/s12262-022-03375-7] [Reference Citation Analysis]
56 Shifman BM, Platonova NM, Vasilyev EV, Abdulkhabirova FM, Kachko VA. Circular RNAs and thyroid cancer: closed molecules, open possibilities. Crit Rev Oncol Hematol 2022;:103662. [PMID: 35341987 DOI: 10.1016/j.critrevonc.2022.103662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Cleere EF, Davey MG, O’neill S, Corbett M, O’donnell JP, Hacking S, Keogh IJ, Lowery AJ, Kerin MJ. Radiomic Detection of Malignancy within Thyroid Nodules Using Ultrasonography—A Systematic Review and Meta-Analysis. Diagnostics 2022;12:794. [DOI: 10.3390/diagnostics12040794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
58 Silaghi H, Lozovanu V, Georgescu CE, Pop C, Nasui BA, Cătoi AF, Silaghi CA. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer. Int J Mol Sci 2022;23:3470. [PMID: 35408830 DOI: 10.3390/ijms23073470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380. [PMID: 35305441 DOI: 10.1016/j.ctrv.2022.102380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
60 Chiapponi C, Alakus H, Schmidt M, Faust M, Bruns CJ, Büttner R, Eich ML, Schultheis AM. Lymphatic Vessel Invasion in Routine Pathology Reports of Papillary Thyroid Cancer. Front Med (Lausanne) 2022;9:841550. [PMID: 35265646 DOI: 10.3389/fmed.2022.841550] [Reference Citation Analysis]
61 Kamani T, Charkhchi P, Zahedi A, Akbari MR. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hered Cancer Clin Pract 2022;20:9. [PMID: 35255942 DOI: 10.1186/s13053-022-00215-3] [Reference Citation Analysis]
62 Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers (Basel) 2022;14:1272. [PMID: 35267580 DOI: 10.3390/cancers14051272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Ding C, Shi T, Wu G, Man J, Han H, Cui Y. The anti-cancer role of microRNA-143 in papillary thyroid carcinoma by targeting high mobility group AT-hook 2. Bioengineered 2022;13:6629-40. [PMID: 35213273 DOI: 10.1080/21655979.2022.2044277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Chen X, Zhang X, Qian Y, Xia E, Wang Y, Zhou Q. Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2. Cell Cycle. [DOI: 10.1080/15384101.2022.2040778] [Reference Citation Analysis]
65 Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E, Do Cao C, Hadoux J. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel) 2022;14:1061. [PMID: 35205809 DOI: 10.3390/cancers14041061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
66 Belousov PV. The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges. Biomedicines 2022;10:468. [DOI: 10.3390/biomedicines10020468] [Reference Citation Analysis]
67 Liu W, Cao W, Dong Z, Cheng R. Can active surveillance management be developed for patients with low-risk papillary thyroid microcarcinoma? A preliminary investigation in a Chinese population. Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.01.013] [Reference Citation Analysis]
68 Schlumberger M, Garcia C, Hadoux J, Klain M, Lamartina L. Functional imaging in thyroid cancer patients with metastases and therapeutic implications. La Presse Médicale 2022. [DOI: 10.1016/j.lpm.2022.104113] [Reference Citation Analysis]
69 Huang C, Yan W, Zhang S, Wu Y, Guo H, Liang K, Xia W, Cong S. Real-Time Elastography: A Web-Based Nomogram Improves the Preoperative Prediction of Central Lymph Node Metastasis in cN0 PTC. Front Oncol 2021;11:755273. [PMID: 35096569 DOI: 10.3389/fonc.2021.755273] [Reference Citation Analysis]
70 Koen K, Robin P, Eline N. CHEK2 mutations and papillary thyroid cancer: correlation or coincidence? Hered Cancer Clin Pract 2022;20:5. [PMID: 35101071 DOI: 10.1186/s13053-022-00211-7] [Reference Citation Analysis]
71 Berinde GM, Socaciu AI, Socaciu MA, Cozma A, Rajnoveanu AG, Petre GE, Piciu D. Thyroid Cancer Diagnostics Related to Occupational and Environmental Risk Factors: An Integrated Risk Assessment Approach. Diagnostics 2022;12:318. [DOI: 10.3390/diagnostics12020318] [Reference Citation Analysis]
72 Dondi F, Pasinetti N, Gatta R, Albano D, Giubbini R, Bertagna F. Comparison between Two Different Scanners for the Evaluation of the Role of 18F-FDG PET/CT Semiquantitative Parameters and Radiomics Features in the Prediction of Final Diagnosis of Thyroid Incidentalomas. J Clin Med 2022;11:615. [PMID: 35160067 DOI: 10.3390/jcm11030615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
73 Chegeni H, Ebrahiminik H, Mosadegh Khah A, Malekzadeh H, Abbasi M, Molooghi K, Fadaee N, Kargar J. Ultrasound-Guided Radiofrequency Ablation of Locally Recurrent Thyroid Carcinoma. Cardiovasc Intervent Radiol. [DOI: 10.1007/s00270-021-03042-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Woo J, Kwon H. Optimal Surgical Extent in Patients with Unilateral Multifocal Papillary Thyroid Carcinoma. Cancers (Basel) 2022;14:432. [PMID: 35053595 DOI: 10.3390/cancers14020432] [Reference Citation Analysis]
75 Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J, Wen P, Zielinski C, Cabanillas M, Boran A, Palanichamy I, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E–mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2021.12.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
76 Wu X, Liu Y, Li K, Yang Y, Lai P, Li J, Kou S. Predictive Value of FNA-Tg and TgAb in Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma. Technol Cancer Res Treat 2022;21:15330338221127605. [PMID: 36128843 DOI: 10.1177/15330338221127605] [Reference Citation Analysis]
77 Bao L, Xu T, Lu X, Huang P, Pan Z, Ge M. Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment. Front Oncol 2021;11:773028. [PMID: 34926283 DOI: 10.3389/fonc.2021.773028] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Cavalieri S, Filippini DM, Ottini A, Bergamini C, Resteghini C, Colombo E, Lombardo R, Nuzzolese I, Alfieri S, Licitra L, Locati LD. Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00062] [Reference Citation Analysis]
79 Grasic Kuhar C, Lozar T, Besic N, Music Marolt M. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia. Adv Ther 2021;38:5684-99. [PMID: 34674146 DOI: 10.1007/s12325-021-01940-2] [Reference Citation Analysis]
80 Censi S, De Rosa A, Galuppini F, Manso J, Bertazza L, Merante-Boschin I, Plebani M, Faggian D, Pennelli G, Barollo S, Vianello F, Iacobone M, Mian C. Can ultrasensitive thyroglobulin immunoassays avoid the need for ultrasound in thyroid cancer follow-up? Endocrine 2021. [PMID: 34800265 DOI: 10.1007/s12020-021-02936-2] [Reference Citation Analysis]
81 Zhou W, Yue Y, Zhang X. Radiotherapy Plus Chemotherapy Leads to Prolonged Survival in Patients With Anaplastic Thyroid Cancer Compared With Radiotherapy Alone Regardless of Surgical Resection and Distant Metastasis: A Retrospective Population Study. Front Endocrinol (Lausanne) 2021;12:748023. [PMID: 34790169 DOI: 10.3389/fendo.2021.748023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. Cancers (Basel) 2021;13:5776. [PMID: 34830930 DOI: 10.3390/cancers13225776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Tsybrovskyy O, De Luise M, de Biase D, Caporali L, Fiorini C, Gasparre G, Carelli V, Hackl D, Imamovic L, Haim S, Sobrinho-Simões M, Tallini G. Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors. J Pathol Clin Res 2021. [PMID: 34792302 DOI: 10.1002/cjp2.247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Grani G, Cera G, Conzo G, Del Gatto V, di Gioia CRT, Maranghi M, Lucia P, Cantisani V, Metere A, Melcarne R, Borcea MC, Scorziello C, Menditto R, Summa M, Biffoni M, Durante C, Giacomelli L. Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension? J Clin Med 2021;10:5277. [PMID: 34830559 DOI: 10.3390/jcm10225277] [Reference Citation Analysis]
85 Shimura H, Matsuzuka T, Suzuki S, Iwadate M, Suzuki S, Yokoya S, Ohira T, Yasumura S, Suzuki S, Ohto H, Kamiya K. Fine Needle Aspiration Cytology Implementation and Malignancy Rates in Children and Adolescents Based on Japanese Guidelines: The Fukushima Health Management Survey. Thyroid 2021;31:1683-92. [PMID: 34762538 DOI: 10.1089/thy.2021.0072] [Reference Citation Analysis]
86 Yang L, Zhang X, Zhang J, Liu Y, Ji T, Mou J, Fang X, Wang S, Chen J. Low expression of TFF3 in papillary thyroid carcinoma may correlate with poor prognosis but high immune cell infiltration. Future Oncol 2021. [PMID: 34756116 DOI: 10.2217/fon-2020-1183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Koehler VF, Fuss CT, Berr CM, Frank-Raue K, Raue F, Hoster E, Hepprich M, Christ E, Pusl T, Reincke M, Spitzweg C, Kroiss M; German Study Group for Rare Malignant Tumours of the Thyroid and Parathyroid Glands. Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. Clin Endocrinol (Oxf) 2021. [PMID: 34743368 DOI: 10.1111/cen.14617] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Woo J, Kim H, Kwon H. Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma. J Clin Med 2021;10:5144. [PMID: 34768664 DOI: 10.3390/jcm10215144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
89 Ratajczak M, Gaweł D, Godlewska M. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update. Int J Mol Sci 2021;22:11829. [PMID: 34769260 DOI: 10.3390/ijms222111829] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
90 Ming J, Zhu JQ, Zhang H, Sun H, Wang J, Cheng RC, Xie L, Li XR, Tian W, Huang T. A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study). BMC Endocr Disord 2021;21:208. [PMID: 34670546 DOI: 10.1186/s12902-021-00871-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Bartz-Kurycki MA, Oluwo OE, Morris-Wiseman LF. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis. Ther Adv Endocrinol Metab 2021;12:20420188211049611. [PMID: 34659736 DOI: 10.1177/20420188211049611] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Fontes LF, do Nascimento MMG, Ramalho-de-Oliveira D, Rezende CP, Costa CHFD, Melo RCR, Brunelli Pujatti P. Clinical pharmaceutical screening in critical situations in a radioiodine therapy management service. J Oncol Pharm Pract 2021;:10781552211045361. [PMID: 34661492 DOI: 10.1177/10781552211045361] [Reference Citation Analysis]
93 Wang X, Niu X, Mu S, Zhang M, Jiang W, Zhai L, Jiang D, Tang W, Zhao C. Analysis and evaluation of the efficacy of ultrasound-guided microwave ablation for papillary thyroid microcarcinoma. Int J Hyperthermia 2021;38:1476-85. [PMID: 34645358 DOI: 10.1080/02656736.2021.1988152] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
94 Lim LS, Lin WC, Chiang PL, Huang SC, Chen YS, Chang YH, Chen WC, Chi SY, Chou CK. One year follow-up of US-Guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: The first experience in Taiwan. J Formos Med Assoc 2021:S0929-6646(21)00472-1. [PMID: 34657768 DOI: 10.1016/j.jfma.2021.09.026] [Reference Citation Analysis]
95 Lin Q, Qi Q, Hou S, Chen Z, Jiang N, Zhang L, Lin C. Activation of the TGF-β1/Smad signaling by KIF2C contributes to the malignant phenotype of thyroid carcinoma cells. Tissue Cell 2021;73:101655. [PMID: 34624565 DOI: 10.1016/j.tice.2021.101655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Riss P, Scheuba K, Strobel O. [Endocrine and neuroendocrine tumors]. Chirurg 2021;92:996-1002. [PMID: 34618164 DOI: 10.1007/s00104-021-01512-8] [Reference Citation Analysis]
97 Silver Karcioglu A, Iwata AJ, Pusztaszeri M, Abdelhamid Ahmed AH, Randolph GW. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines. Cancer Cytopathol 2021. [PMID: 34618407 DOI: 10.1002/cncy.22519] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
98 de la Fouchardière C, Wassermann J, Calcagno F, Bardet S, Al Ghuzlan A, Borget I, Borson Chazot F, Do Cao C, Buffet C, Zerdoud S, Decaussin-Petrucci M, Godbert Y, Leboulleux S. [Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network]. Bull Cancer 2021;108:1044-56. [PMID: 34593218 DOI: 10.1016/j.bulcan.2021.06.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Kim H, Kwon H, Moon BI. Association of Multifocality With Prognosis of Papillary Thyroid Carcinoma: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg 2021;147:847-54. [PMID: 34410321 DOI: 10.1001/jamaoto.2021.1976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
100 Klain M, Zampella E, Nappi C, Nicolai E, Ambrosio R, Califaretti E, Lamartina L, Schlumberger M, Deandreis D, Salvatore D, Cuocolo A. Advances in Functional Imaging of Differentiated Thyroid Cancer. Cancers (Basel) 2021;13:4748. [PMID: 34638232 DOI: 10.3390/cancers13194748] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
101 Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, Durante C, Castagna MG. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid 2021. [PMID: 34541894 DOI: 10.1089/thy.2021.0248] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
102 Huang S, Wu Y, Li C, Xu L, Huang J, Huang Y, Cheng W, Xue B, Zhang L, Liang S, Jin X, Zhu X, Xiong S, Su Y, Wang H. Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and therapy. Nanoscale 2021;13:15021-30. [PMID: 34533142 DOI: 10.1039/d1nr02892h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Shimura H, Matsumoto Y, Murakami T, Fukunari N, Kitaoka M, Suzuki S. Diagnostic Strategies for Thyroid Nodules Based on Ultrasonographic Findings in Japan. Cancers (Basel) 2021;13:4629. [PMID: 34572857 DOI: 10.3390/cancers13184629] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
104 Guo K, Qian K, Shi Y, Sun T, Chen L, Mei D, Dong K, Gu S, Liu J, Lv Z, Wang Z. Clinical and Molecular Characterizations of Papillary Thyroid Cancer in Children and Young Adults: A Multicenter Retrospective Study. Thyroid 2021;31:1693-706. [PMID: 34514877 DOI: 10.1089/thy.2021.0003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
105 de la Fouchardière C, Godbert Y, Dalban C, Illouz F, Wassermann J, Do Cao C, Bardet S, Zerdoud S, Chougnet CN, Zalzali M, Benisvy D, Niccoli P, Digue L, Lamartina L, Schwartz P, Borson Chazot F, Gautier J, Pérol D, Leboulleux S; PAZOTHYR investigators. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. Eur J Cancer 2021;157:153-64. [PMID: 34509954 DOI: 10.1016/j.ejca.2021.07.029] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
106 Lee H, Paeng JC, Choi H, Cho SW, Park YJ, Park DJ, Lee YA, Chung JK, Kang KW, Cheon GJ. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration. PLoS One 2021;16:e0256727. [PMID: 34492048 DOI: 10.1371/journal.pone.0256727] [Reference Citation Analysis]
107 Kiesewetter B, Riss P, Scheuba C, Mazal P, Kretschmer-Chott E, Haug A, Raderer M. Management of adrenocortical carcinoma: are we making progress? Ther Adv Med Oncol 2021;13:17588359211038409. [PMID: 34484430 DOI: 10.1177/17588359211038409] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
108 Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. J Nucl Med 2021;62:1221-7. [PMID: 33547213 DOI: 10.2967/jnumed.120.252791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ma T, Wang H, Liu J, Zou J, Liu S. Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma? Front Endocrinol (Lausanne) 2021;12:723631. [PMID: 34434171 DOI: 10.3389/fendo.2021.723631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Hîțu L, Ștefan PA, Piciu D. Total Tumor Diameter and Unilateral Multifocality as Independent Predictor Factors for Metastatic Papillary Thyroid Microcarcinoma. J Clin Med 2021;10:3707. [PMID: 34442001 DOI: 10.3390/jcm10163707] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
111 Krajewska J, Kukulska A, Oczko-wojciechowska M, Jarzab B. Recent advances in precision medicine for the treatment of medullary thyroid cancer. Expert Review of Precision Medicine and Drug Development 2021;6:307-15. [DOI: 10.1080/23808993.2021.1964952] [Reference Citation Analysis]
112 Wu J, Zhao ZL, Cao XJ, Wei Y, Peng LL, Li Y, Yu MA. A feasibility study of microwave ablation for papillary thyroid cancer close to the thyroid capsule. Int J Hyperthermia 2021;38:1217-24. [PMID: 34384314 DOI: 10.1080/02656736.2021.1962549] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
113 Fröhlich E, Wahl R. Nanoparticles: Promising Auxiliary Agents for Diagnosis and Therapy of Thyroid Cancers. Cancers (Basel) 2021;13:4063. [PMID: 34439219 DOI: 10.3390/cancers13164063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
114 Ahn JH, Kwak JH, Yoon SG, Yi JW, Yu HW, Kwon H, Kim SJ, Lee KE. A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma. Surgery 2021:S0039-6060(21)00611-5. [PMID: 34391573 DOI: 10.1016/j.surg.2021.03.071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
115 Walczyk A, Zgubieński K, Chmielewski G, Hińcza-Nowak K, Kowalik A, Jaskulski J, Kowalska A. Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. Diagnostics (Basel) 2021;11:1448. [PMID: 34441382 DOI: 10.3390/diagnostics11081448] [Reference Citation Analysis]
116 Boucher A, Ezzat S, Hotte S, Rachinsky I, Rajaraman M, Ruether D, Wiseman SM, Brierley J, Ho C, Krzyzanowska M, Lamond N, Massicotte MH, Joseph S, Herscovitch K, Sikora L, Winquist E. Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. Oral Oncol 2021;121:105477. [PMID: 34388408 DOI: 10.1016/j.oraloncology.2021.105477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Ferrari C, Santo G, Ruta R, Lavelli V, Rubini D, Mammucci P, Sardaro A, Rubini G. Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT. Diagnostics (Basel) 2021;11:1417. [PMID: 34441351 DOI: 10.3390/diagnostics11081417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Jungels C. Editorial: Endocrine tumors, rare tumors. Curr Opin Oncol 2021;33:1-2. [PMID: 33273300 DOI: 10.1097/CCO.0000000000000690] [Reference Citation Analysis]
119 Allegri L, Capriglione F, Maggisano V, Damante G, Baldan F. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells. Int J Mol Sci 2021;22:8083. [PMID: 34360846 DOI: 10.3390/ijms22158083] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
120 Broecker-Preuss M, Mehnert I, Gilman E, Herrmann K, Weber M, Görges R. Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assays. Pract Lab Med 2021;26:e00250. [PMID: 34386567 DOI: 10.1016/j.plabm.2021.e00250] [Reference Citation Analysis]
121 Romano C, Martorana F, Pennisi MS, Stella S, Massimino M, Tirrò E, Vitale SR, Di Gregorio S, Puma A, Tomarchio C, Manzella L. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer. Int J Mol Sci 2021;22:7707. [PMID: 34299334 DOI: 10.3390/ijms22147707] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
122 Song Y, Liu F, Ruan W, Hu F, Younis MH, Gao Z, Ming J, Huang T, Cai W, Lan X. Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment. Cancers (Basel) 2021;13:3436. [PMID: 34298651 DOI: 10.3390/cancers13143436] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
123 Wada Y, Anbai A, Kumagai S, Okuyama E, Takagi N, Hashimoto M. Treatment Outcomes of External Beam Radiation Therapy for Unresectable Locally Advanced Thyroid Cancer with or without Metastasis: A Retrospective Single-Center Study. Radiation 2021;1:174-82. [DOI: 10.3390/radiation1030016] [Reference Citation Analysis]
124 Szumowski P, Abdelrazek S, Iwanicka D, Mojsak M, Sykała M, Żukowski Ł, Siewko K, Adamska A, Maliszewska K, Popławska-Kita A, Szelachowska M, Krętowski A, Myśliwiec J. Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications. Sci Rep 2021;11:13930. [PMID: 34230618 DOI: 10.1038/s41598-021-93431-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Wang HH, Ma JN, Zhan XR. Circular RNA Circ_0067934 Attenuates Ferroptosis of Thyroid Cancer Cells by miR-545-3p/SLC7A11 Signaling. Front Endocrinol (Lausanne) 2021;12:670031. [PMID: 34290668 DOI: 10.3389/fendo.2021.670031] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
126 Song Q, Gao H, Ren L, Tian X, Lan Y, Yan L, Luo Y. Radiofrequency ablation versus total thyroidectomy in patients with papillary thyroid microcarcinoma located in the isthmus: a retrospective cohort study. Int J Hyperthermia 2021;38:708-14. [PMID: 33899651 DOI: 10.1080/02656736.2021.1916625] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
127 Drumond EF, Drummond MCF. Thyroid cancer in Brazil: what the Hospital Cancer Records say and what they don't say. Epidemiol Serv Saude 2021;30:e2020927. [PMID: 34190876 DOI: 10.1590/S1679-49742021000300025] [Reference Citation Analysis]
128 Besic N, Vidergar-Kralj B, Zaletel K, Grasic-Kuhar C. Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report. Medicine (Baltimore) 2021;100:e26384. [PMID: 34160415 DOI: 10.1097/MD.0000000000026384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Kim M, Kim BH. Current Guidelines for Management of Medullary Thyroid Carcinoma. Endocrinol Metab (Seoul) 2021;36:514-24. [PMID: 34154310 DOI: 10.3803/EnM.2021.1082] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
130 Augustin T, Oliinyk D, Rauch J, Koehler VF, Spitzweg C, Belka C, KÄsmann L. Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer. In Vivo 2021;35:461-5. [PMID: 33402497 DOI: 10.21873/invivo.12279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Jones H, Green V, England J, Greenman J. Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review. Future Sci OA 2021;7:FSO738. [PMID: 34258030 DOI: 10.2144/fsoa-2021-0041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Dotinga M, Vriens D, van Velden F, Heijmen L, Nagarajah J, Hicks R, Kapiteijn E, de Geus-Oei LF. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Q J Nucl Med Mol Imaging 2020;64:250-64. [PMID: 32744039 DOI: 10.23736/S1824-4785.20.03264-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
133 Watkins L, O'Neill G, Young D, McArthur C. Comparison of British Thyroid Association, American College of Radiology TIRADS and Artificial Intelligence TIRADS with histological correlation: diagnostic performance for predicting thyroid malignancy and unnecessary fine needle aspiration rate. Br J Radiol 2021;94:20201444. [PMID: 33989038 DOI: 10.1259/bjr.20201444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Kiesewetter B, Riss P, Scheuba C, Raderer M. How I treat medullary thyroid cancer. ESMO Open 2021;6:100183. [PMID: 34091261 DOI: 10.1016/j.esmoop.2021.100183] [Reference Citation Analysis]
135 Gajowiec A, Chromik A, Furga K, Skuza A, Gąsior-Perczak D, Walczyk A, Pałyga I, Trybek T, Mikina E, Szymonek M, Gadawska-Juszczyk K, Kuchareczko A, Suligowska A, Jaskulski J, Orłowski P, Chrapek M, Góźdź S, Kowalska A. Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer? J Clin Med 2021;10:2438. [PMID: 34072690 DOI: 10.3390/jcm10112438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Mauri G, Hegedüs L, Bandula S, Cazzato RL, Czarniecka A, Dudeck O, Fugazzola L, Netea-Maier R, Russ G, Wallin G, Papini E. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions. Eur Thyroid J 2021;10:185-97. [PMID: 34178704 DOI: 10.1159/000516469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
137 Cao Y, Zhong X, Diao W, Mu J, Cheng Y, Jia Z. Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations. Cancers (Basel) 2021;13:2436. [PMID: 34069887 DOI: 10.3390/cancers13102436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
138 Nervo A, Ragni A, Retta F, Calandri M, Gazzera C, Gallo M, Piovesan A, Arvat E. Interventional Radiology Approaches for Liver Metastases from Thyroid Cancer: A Case Series and Overview of the Literature. J Gastrointest Cancer 2021;52:823-32. [PMID: 33999355 DOI: 10.1007/s12029-021-00646-6] [Reference Citation Analysis]
139 Asa S, Sonmezoglu K, Uslu-Besli L, Sahin OE, Karayel E, Pehlivanoglu H, Sager S, Kabasakal L, Ocak M, Sayman HB. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann Nucl Med 2021;35:900-15. [PMID: 33993425 DOI: 10.1007/s12149-021-01627-2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
140 Bunevicius A, Fribance S, Pikis S, Lee JYK, Buch LY, Moran M, Yang AI, Bernstein K, Mathieu D, Perron R, Liscak R, Simonova G, Patel S, Trifiletti DM, Martínez Álvarez R, Martínez Moreno N, Lee CC, Yang HC, Strickland BA, Zada G, Chang EL, Kondziolka D, Sheehan J. Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study. Thyroid 2021;31:1244-52. [PMID: 33978475 DOI: 10.1089/thy.2020.0947] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
141 Fukuda N, Takahashi S. Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers (Basel) 2021;13:2279. [PMID: 34068664 DOI: 10.3390/cancers13092279] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
142 Ding H, Wang X, Liu H, Na L. Higher circular RNA_0015278 correlates with absence of extrathyroidal invasion, lower pathological tumor stages, and prolonged disease-free survival in papillary thyroid carcinoma patients. J Clin Lab Anal 2021;35:e23819. [PMID: 33969549 DOI: 10.1002/jcla.23819] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
143 Van Den Heede K, Tolley NS, Di Marco AN, Palazzo FF. Differentiated Thyroid Cancer: A Health Economic Review. Cancers (Basel) 2021;13:2253. [PMID: 34067214 DOI: 10.3390/cancers13092253] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
144 Kaewchur T, Namwongprom S, Waisayanand N, Pongwiwattanachai W, Ekmahachai M. Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma. J ASEAN Fed Endocr Soc 2021;36:64-8. [PMID: 34177090 DOI: 10.15605/jafes.036.01.10] [Reference Citation Analysis]
145 Chen Z, Zhong Z, Chen G, Feng Y. Application of Carbon Nanoparticles in Neck Dissection of Clinically Node-Negative Papillary Thyroid Carcinoma. Biomed Res Int 2021;2021:6693585. [PMID: 33969124 DOI: 10.1155/2021/6693585] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
146 Zhang X, Zhang X, Du W, Dai L, Luo R, Fang Q, Ge H. Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 2021;12:663720. [PMID: 33912138 DOI: 10.3389/fendo.2021.663720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Li S, Yang T, Xiang Y, Li X, Zhang L, Deng S. Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary. BMC Cancer 2021;21:383. [PMID: 33836675 DOI: 10.1186/s12885-021-08118-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
148 Imperiale A, Meuter L, Pacak K, Taïeb D. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Semin Nucl Med 2021;51:519-28. [PMID: 33838874 DOI: 10.1053/j.semnuclmed.2021.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
149 Kunjumohamed FP, Al Rawahi A, Al Busaidi NB, Al Musalhi HN. Disease-free Survival of Patients with Differentiated Thyroid Cancer: A Study from a Tertiary Center in Oman. Oman Med J 2021;36:e246. [PMID: 33854795 DOI: 10.5001/omj.2021.54] [Reference Citation Analysis]
150 Juweid ME, Rabadi NJ, Tulchinsky M, Aloqaily M, Al-Momani A, Arabiat M, Abu Ain G, Al Hawari H, Al-Momani M, Mismar A, Abulaban A, Taha I, Alhouri A, Zayed A, Albsoul N, Al-Abbadi MA. Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan. Endocrine 2021;73:633-40. [PMID: 33772746 DOI: 10.1007/s12020-021-02698-x] [Reference Citation Analysis]
151 Webb JM, Meixner DD, Adusei SA, Polley EC, Fatemi M, Alizad A. Automatic Deep Learning Semantic Segmentation of Ultrasound Thyroid Cineclips Using Recurrent Fully Convolutional Networks. IEEE Access 2021;9:5119-27. [PMID: 33747681 DOI: 10.1109/access.2020.3045906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Akhtar N, Chakrabarti D, Rajan S, Kumar V, Qayoom S, Chaturvedi A, Bhatt MLB. Is a laryngectomy justified for all histological subtypes of thyroid cancers as a part of gross total excision? J Surg Oncol 2021;123:1649-50. [PMID: 33730399 DOI: 10.1002/jso.26324] [Reference Citation Analysis]
153 Zhen J, Song Z, Su W, Zeng QC, Li J, Sun Q. Integrated analysis of RNA-binding proteins in thyroid cancer. PLoS One 2021;16:e0247836. [PMID: 33711033 DOI: 10.1371/journal.pone.0247836] [Reference Citation Analysis]
154 Azadnajafabad S, Saeedi Moghaddam S, Mohammadi E, Rezaei N, Ghasemi E, Fattahi N, Aminorroaya A, Azadnajafabad R, Aryannejad A, Rezaei N, Naderimagham S, Haghpanah V, Mokdad AH, Gharib H, Farzadfar F, Larijani B. Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990-2017. Cancer Med 2021;10:2496-508. [PMID: 33665966 DOI: 10.1002/cam4.3823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
155 Soares P, Póvoa AA, Melo M, Vinagre J, Máximo V, Eloy C, Cameselle-Teijeiro JM, Sobrinho-Simões M. Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. Endocr Pathol 2021;32:44-62. [PMID: 33651322 DOI: 10.1007/s12022-021-09666-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
156 Mcleod DSA. Withholding Radioactive Iodine for Lower-Risk Papillary Thyroid Cancers Is Safe, but Delays the Certainty of Treatment Response. Clinical Thyroidology 2021;33:117-20. [DOI: 10.1089/ct.2021;33.117-120] [Reference Citation Analysis]
157 Grani G, Sponziello M, Pecce V, Ramundo V, Durante C. Contemporary Thyroid Nodule Evaluation and Management. J Clin Endocrinol Metab 2020;105:dgaa322. [PMID: 32491169 DOI: 10.1210/clinem/dgaa322] [Cited by in Crossref: 17] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
158 Sanz-Martín B, Aguillo-Gutiérrez E, Román-Gimeno S, Urdániz-Borque R, Ortez-Toro JJ, Peteiro-Miranda CM. Case report: Thyroglossal duct cyst papillary carcinoma in a young male. Ann Endocrinol (Paris) 2021;82:126-8. [PMID: 33636183 DOI: 10.1016/j.ando.2021.01.001] [Reference Citation Analysis]
159 Suoh M, Hagihara A, Yamamura M, Maruyama H, Taira K, Enomoto M, Tamori A, Fujiwara Y, Kawada N. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma. Intern Med 2021;60:545-52. [PMID: 33028766 DOI: 10.2169/internalmedicine.5097-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
161 Rui Z, Wu R, Zheng W, Wang X, Meng Z, Tan J. Effect of ¹³¹I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer. Med Sci Monit 2021;27:e929590. [PMID: 33568620 DOI: 10.12659/MSM.929590] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
162 Song Q, Gao H, Tian X, Ren L, Lan Y, Yan L, Luo Y. Evaluation of Ultrasound-Guided Radiofrequency Ablation as a Treatment Option for Papillary Thyroid Microcarcinoma in the Isthmus: A Retrospective Study. Front Endocrinol (Lausanne) 2020;11:599471. [PMID: 33633683 DOI: 10.3389/fendo.2020.599471] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
163 Dou Y, Chen Y, Hu D, Su X. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study. Front Endocrinol (Lausanne) 2020;11:619841. [PMID: 33633689 DOI: 10.3389/fendo.2020.619841] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
164 Hardiyanto H, Avanti WS, Dwianingsih EK, Anwar SL. Extrathyroidal extension ventrally to the thoracic wall of a papillary thyroid carcinoma. BMJ Case Rep 2021;14:e239233. [PMID: 33541997 DOI: 10.1136/bcr-2020-239233] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
165 Ramundo V, Di Gioia CRT, Falcone R, Lamartina L, Biffoni M, Giacomelli L, Filetti S, Durante C, Grani G. Diagnostic Performance of Neck Ultrasonography in the Preoperative Evaluation for Extrathyroidal Extension of Suspicious Thyroid Nodules. World J Surg 2020;44:2669-74. [PMID: 32193621 DOI: 10.1007/s00268-020-05482-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
166 Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol 2021;28:523-48. [PMID: 33467570 DOI: 10.3390/curroncol28010053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
167 Masaki C, Sugino K, Ito K. Clinical management of low-risk papillary thyroid microcarcinoma. Minerva Endocrinol (Torino) 2021;46:413-27. [PMID: 33435642 DOI: 10.23736/S0391-1977.20.03283-6] [Reference Citation Analysis]
168 Grani G, Lamartina L, Alfò M, Ramundo V, Falcone R, Giacomelli L, Biffoni M, Filetti S, Durante C. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk. J Clin Endocrinol Metab 2021;106:e1717-27. [PMID: 33377969 DOI: 10.1210/clinem/dgaa973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
169 Pitt SC, Yang N, Saucke MC, Marka N, Hanlon B, Long KL, McDow AD, Brito JP, Roman BR. Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey. J Clin Endocrinol Metab 2021;106:e1728-37. [PMID: 33373458 DOI: 10.1210/clinem/dgaa942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
170 Sawant R, FitzGerald A, Hey SY, Hulse K, Hay A, Adamson R, Nixon IJ. Oncological outcomes in differentiated thyroid cancer in South East Scotland. Surgeon 2020:S1479-666X(20)30176-1. [PMID: 33358594 DOI: 10.1016/j.surge.2020.11.003] [Reference Citation Analysis]
171 Castinetti F, Taïeb D. Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal? Thyroid 2021;31:151-5. [PMID: 33191866 DOI: 10.1089/thy.2020.0674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
172 Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 2021;17:176-88. [PMID: 33339988 DOI: 10.1038/s41574-020-00448-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 20.5] [Reference Citation Analysis]
173 Sorrenti S, Carbotta G, Di Matteo FM, Catania A, Pironi D, Tartaglia F, Tarroni D, Gagliardi F, Tripodi D, Watanabe M, Mariani S, D'Armiento E, Fallahi P, Sindoni A, De Vito C, Antonelli A, Ulisse S, Baldini E. Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. Cancers (Basel) 2020;12:E3637. [PMID: 33291668 DOI: 10.3390/cancers12123637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
174 Eilsberger F, Verburg FA. Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer. Clin Oncol (R Coll Radiol) 2021;33:68-74. [PMID: 33250287 DOI: 10.1016/j.clon.2020.11.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Suwardjo S, Avanti WS, Dwianingsih EK, Harahap WA, Anwar SL. Complete diaphysis resorption of the femur: A case report in a metastatic papillary thyroid cancer. Ann Med Surg (Lond) 2020;60:614-8. [PMID: 33304574 DOI: 10.1016/j.amsu.2020.11.076] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
176 Tourani SS, Fleming B, Gundara J. Value of thyroglobulin post hemithyroidectomy for cancer: a literature review. ANZ J Surg 2021;91:724-9. [PMID: 33244886 DOI: 10.1111/ans.16459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Colombo C, Giancola N, Fugazzola L. Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinol (Torino) 2021;46:62-89. [PMID: 33213119 DOI: 10.23736/S2724-6507.20.03342-8] [Reference Citation Analysis]
178 Asimakopoulos P, Shaha AR, Nixon IJ, Shah JP, Randolph GW, Angelos P, Zafereo ME, Kowalski LP, Hartl DM, Olsen KD, Rodrigo JP, Vander Poorten V, Mäkitie AA, Sanabria A, Suárez C, Quer M, Civantos FJ, Robbins KT, Guntinas-Lichius O, Hamoir M, Rinaldo A, Ferlito A. Management of the Neck in Well-Differentiated Thyroid Cancer. Curr Oncol Rep 2020;23:1. [PMID: 33190176 DOI: 10.1007/s11912-020-00997-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
179 Giuliano S, Mirabelli M, Chiefari E, Vergine M, Gervasi R, Brunetti FS, Innaro N, Donato G, Aversa A, Brunetti A. Malignancy Analyses of Thyroid Nodules in Patients Subjected to Surgery with Cytological- and Ultrasound-Based Risk Stratification Systems. Endocrines 2020;1:102-18. [DOI: 10.3390/endocrines1020010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
180 Kharroubi D, Richa C, Saie C, Chami L, Lussey-Lepoutre C. Solitary Breast Metastasis From Thyroid Papillary Carcinoma Revealed on Whole-Body Radioactive 131I Scan. Clin Nucl Med 2020;45:687-8. [PMID: 32453076 DOI: 10.1097/RLU.0000000000003115] [Reference Citation Analysis]
181 Grossrubatscher E, Fanciulli G, Pes L, Sesti F, Dolci C, de Cicco F, Colao A, Faggiano A, Nike Group. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. J Clin Med 2020;9:E3507. [PMID: 33138305 DOI: 10.3390/jcm9113507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
182 Hitu L, Gabora K, Bonci EA, Piciu A, Hitu AC, Ștefan PA, Piciu D. MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020. Cancers (Basel) 2020;12:E3118. [PMID: 33113852 DOI: 10.3390/cancers12113118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
183 Chiacchiarini M, Trocchianesi S, Besharat ZM, Po A, Ferretti E. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer. Pharmacol Ther 2021;219:107708. [PMID: 33091426 DOI: 10.1016/j.pharmthera.2020.107708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
184 Augustin T, Oliinyk D, Köhler VF, Rauch J, Belka C, Spitzweg C, Käsmann L. Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients. J Clin Med 2020;9:E3231. [PMID: 33050286 DOI: 10.3390/jcm9103231] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
185 Basım P, Argun D, Özdenkaya Y. Self-reported medication adherence in differentiated thyroid cancer survivors: Role of illness perception and medication beliefs. Head Neck 2021;43:428-37. [PMID: 33009715 DOI: 10.1002/hed.26488] [Reference Citation Analysis]
186 Jung CK, Lee S, Bae JS, Lim DJ. Late-onset distant metastases confer poor prognosis in patients with well-differentiated thyroid cancer. Gland Surg 2020;9:1857-66. [PMID: 33224861 DOI: 10.21037/gs-20-416] [Reference Citation Analysis]
187 Cao S, Yu S, Yin Y, Su L, Hong S, Gong Y, Lv W, Li Y, Xiao H. Genetic alterations in cfDNA of benign and malignant thyroid nodules based on amplicon-based next-generation sequencing. Ann Transl Med 2020;8:1225. [PMID: 33178757 DOI: 10.21037/atm-20-4544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid 2021;31:459-69. [PMID: 32781914 DOI: 10.1089/thy.2020.0206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
189 Trimboli P, Castellana M, Piccardo A, Romanelli F, Grani G, Giovanella L, Durante C. The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma. A meta-analysis. Rev Endocr Metab Disord 2021;22:453-60. [PMID: 32959174 DOI: 10.1007/s11154-020-09592-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
190 Li SY, Ding YQ, Si YL, Ye MJ, Xu CM, Qi XP. 5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine. Front Endocrinol (Lausanne) 2020;11:543246. [PMID: 33071967 DOI: 10.3389/fendo.2020.543246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. Biomed Hub 2020;5:182-223. [PMID: 33564664 DOI: 10.1159/000511209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
192 Oliinyk D, Augustin T, Koehler VF, Rauch J, Belka C, Spitzweg C, Käsmann L. Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis. Cancers (Basel) 2020;12:E2506. [PMID: 32899355 DOI: 10.3390/cancers12092506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
193 Liu W, Yan X, Cheng R. Continuing controversy regarding individualized surgical decision-making for patients with 1-4 cm low-risk differentiated thyroid carcinoma: A systematic review. Eur J Surg Oncol 2020;46:2174-84. [PMID: 32933805 DOI: 10.1016/j.ejso.2020.08.014] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
194 Veschi V, Verona F, Lo Iacono M, D'Accardo C, Porcelli G, Turdo A, Gaggianesi M, Forte S, Giuffrida D, Memeo L, Todaro M. Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis. Front Endocrinol (Lausanne) 2020;11:566. [PMID: 32982967 DOI: 10.3389/fendo.2020.00566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
195 Huang C, Cong S, Liang T, Feng Z, Gan K, Zhou R, Guo Y, Luo S, Liang K, Wang Q. Development and validation of an ultrasound-based nomogram for preoperative prediction of cervical central lymph node metastasis in papillary thyroid carcinoma. Gland Surg 2020;9:956-67. [PMID: 32953605 DOI: 10.21037/gs-20-75] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
196 Weber F, Dralle H. [Completion thyroidectomy after less than total resection for postoperatively diagnosed follicular thyroid cancer]. Chirurg 2020;91:1007-12. [PMID: 32710159 DOI: 10.1007/s00104-020-01247-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Castellnou S, Lifante JC, Polazzi S, Pascal L, Borson-Chazot F, Duclos A. Influence of Care Pathway on Thyroid Nodule Surgery Relevance: A Historical Cohort Study. J Clin Med 2020;9:E2271. [PMID: 32708905 DOI: 10.3390/jcm9072271] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
198 San Román Gil M, Pozas J, Molina-Cerrillo J, Gómez J, Pian H, Pozas M, Carrato A, Grande E, Alonso-Gordoa T. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. Int J Mol Sci 2020;21:E4951. [PMID: 32668761 DOI: 10.3390/ijms21144951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Rosario PW, Mourão GF, Calsolari MR. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine? Endocrine 2020;70:552-7. [DOI: 10.1007/s12020-020-02414-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Grani G, Zatelli MC, Alfò M, Montesano T, Torlontano M, Morelli S, Deandrea M, Antonelli A, Francese C, Ceresini G, Orlandi F, Maniglia CA, Bruno R, Monti S, Santaguida MG, Repaci A, Tallini G, Fugazzola L, Monzani F, Giubbini R, Rossetto R, Mian C, Crescenzi A, Tumino D, Pagano L, Pezzullo L, Lombardi CP, Arvat E, Petrone L, Castagna MG, Spiazzi G, Salvatore D, Meringolo D, Solaroli E, Monari F, Magri F, Triggiani V, Castello R, Piazza C, Rossi R, Ferraro Petrillo U, Filetti S, Durante C. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. Thyroid 2021;31:264-71. [PMID: 32475305 DOI: 10.1089/thy.2020.0272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
201 Gugnoni M, Manicardi V, Torricelli F, Sauta E, Bellazzi R, Manzotti G, Vitale E, de Biase D, Piana S, Ciarrocchi A. Linc00941 Is a Novel Transforming Growth Factor β Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6. Thyroid 2021;31:247-63. [PMID: 32495722 DOI: 10.1089/thy.2020.0001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
202 Tuncel M, Kılıçkap S, Süslü N. Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer. Ann Nucl Med 2020;34:663-74. [PMID: 32602032 DOI: 10.1007/s12149-020-01494-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
203 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Prophylactic lymph node dissection in clinically N0 differentiated thyroid carcinoma: example of personalized treatment. Per Med 2020;17:317-38. [PMID: 32588744 DOI: 10.2217/pme-2019-0119] [Reference Citation Analysis]
204 Falcone R, Grani G, Ramundo V, Melcarne R, Giacomelli L, Filetti S, Durante C. Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies. Front Oncol 2020;10:1128. [PMID: 32714873 DOI: 10.3389/fonc.2020.01128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
205 Amaral M, Afonso RA, Gaspar MM, Reis CP. Anaplastic thyroid cancer: How far can we go? EXCLI J 2020;19:800-12. [PMID: 32636733 DOI: 10.17179/excli2020-1302] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
206 Verrienti A, Pecce V, Abballe L, Ramundo V, Falcone R, Inanloo Nigi Jak F, Brunelli C, Fadda G, Bosco D, Ascoli V, Carletti R, Di Gioia C, Grani G, Sponziello M. Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue. Endocrine 2020;69:451-5. [PMID: 32506194 DOI: 10.1007/s12020-020-02372-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
207 Lombardi CP, D'Amore A, Grani G, Ramundo V, Boscherini M, Gordini L, Marzi F, Tedesco S, Bocale R. Endocrine surgery during COVID-19 pandemic: do we need an update of indications in Italy? Endocrine 2020;68:485-8. [PMID: 32500518 DOI: 10.1007/s12020-020-02357-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
208 Dabelić N, Jukić T, Fröbe A. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Acta Clin Croat 2020;59:50-9. [PMID: 34219884 DOI: 10.20471/acc.2020.59.s1.06] [Reference Citation Analysis]
209 Takinami M, Yokota T. Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma. Case Rep Oncol 2020;13:522-7. [PMID: 32518548 DOI: 10.1159/000507344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
210 Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers (Basel) 2020;12:E731. [PMID: 32244867 DOI: 10.3390/cancers12030731] [Cited by in Crossref: 55] [Cited by in F6Publishing: 114] [Article Influence: 27.5] [Reference Citation Analysis]
211 Hitu L, Cainap C, Apostu D, Gabora K, Bonci EA, Badan M, Mester A, Piciu A. Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT. Diagnostics (Basel) 2020;10:E100. [PMID: 32059570 DOI: 10.3390/diagnostics10020100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
212 Gallardo E, Medina J, Sánchez JC, Viúdez A, Grande E, Porras I, Ramón Y Cajal T, Trigo J, Iglesias L, Capdevila J. SEOM clinical guideline thyroid cancer (2019). Clin Transl Oncol 2020;22:223-35. [PMID: 32006340 DOI: 10.1007/s12094-019-02284-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
213 Seok J, Choi JY, Yu HW, Jung YH, Ahn SH, Jeong WJ. Papillary Thyroid Cancers of the Thyroid Isthmus: The Pattern of Nodal Metastasis and the Significance of Extrathyroidal Extension. Ann Surg Oncol 2020;27:1937-44. [PMID: 31970571 DOI: 10.1245/s10434-020-08215-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
214 Nixon IJ, Shah JP, Zafereo M, Simo RS, Hay ID, Suárez C, Zbären P, Rinaldo A, Sanabria A, Silver C, Mäkitie A, Vander Poorten V, Kowalski LP, Shaha AR, Randolph GW, Ferlito A. The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective. Eur J Surg Oncol 2020;46:754-62. [PMID: 31952928 DOI: 10.1016/j.ejso.2020.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
215 Lungulescu C, Croitoru VM, Lungulescu C, Croitoru A, Paul D. DURABLE RESPONSE IN A CASE OF METASTATIC ANAPLASTIC THYROID CANCER USING A COMBINATION OF TYROSINE KINASE INHIBITORS AND A CHECK POINT INHIBITOR. Acta Endocrinol (Buchar) 2020;16:236-41. [PMID: 33029242 DOI: 10.4183/aeb.2020.236] [Cited by in F6Publishing: 1] [Reference Citation Analysis]